Bioventures Investors

What Bioventures Investors does

Bioventures Investors (operating as BioVentures MedTech Funds) is a Wellesley/Westborough, Massachusetts-based venture capital firm founded in 1998 by Peter Feinstein and Marc Goldberg that invests exclusively in medical technology. It manages two dedicated funds: the Growth Capital Fund, which deploys $10-25MM into companies that have essentially completed development and regulatory milestones and target exit within 36 months, and the Innovation Fund, which deploys $5-10MM (often across tranches) into development-stage companies targeting 4-6 year exits. The firm takes board seats in most investments and supports portfolio companies across therapeutic devices, diagnostics, imaging, and healthcare IT.

The firm serves emerging and growth-stage MedTech entrepreneurs and operators by providing capital, board-level governance, and access to a global syndication and LP co-investment network. Its core "technology" is concentrated sector expertise: a partner bench with 20-35+ years each in healthcare investing, clinical practice (vascular surgery, cardiac surgery, gastroenterology, bariatric endoscopy), regulatory affairs, and corporate operating roles (Genetics Institute, Biogen, Hewlett-Packard medical products, Oxford Bioscience Partners, Leerink Swann, Johnson & Johnson/Janssen, Waterfall Asset Management). The firm has executed 30+ investments and 20+ exits since inception.

Revenue is generated through the standard VC model: management fees on committed/deployed capital across the two funds and carried interest from successful portfolio exits (e.g., CareSignal Q4 2021, ArthroSurface/Anika 2020, Spirus/Olympus 2011, AngioLink/Medtronic 2004). The firm operates with 1-10 employees and relies on a referral-driven, direct-submission go-to-market, with deal review by the investment team in weekly meetings and unanimous investment committee approval required to fund.

Name

Bioventures Investors

Legal name

BioVentures MedTech Funds

Website

https://bioventuresinvestors.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Bioventures Investors (BioVentures MedTech Funds) is a Massachusetts-based venture capital firm founded in 1998 that invests exclusively in medical technology companies through two funds: a $10-25MM Growth Capital Fund and a $5-10MM Innovation Fund, serving emerging and growth-stage MedTech entrepreneurs with board support and global syndication.

Ownership category

akta.pro rank

Headquarters

HQ city

Wellesley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management and Carried Interest: As a venture capital fund, BioVentures generates returns through management fees on deployed capital and carried interest from successful portfolio company exits. The firm manages two main funds: Growth Capital Fund targeting $10-25MM investments and Innovation Fund targeting $5-10MM investments.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

BioVentures MedTech Funds is a venture capital firm that invests growth capital into medical technology companies across two distinct funds: the Growth Capital Fund, which deploys $10-25MM into MedTech companies that have removed development and regulatory risk and are entering a growth phase targeted at exit within three years; and the Innovation Fund, which deploys $5-10MM (often across multiple tranches) into MedTech companies still in the development phase with anticipated exits within four to six years. In addition to capital, the firm provides active board-level guidance, regulatory and clinical expertise, and access to a global investor syndication network.

Product overview

BioVentures MedTech Funds operates as a dual-fund venture capital firm specializing in the MedTech sector. The company offers two distinct investment products: the Growth Capital Fund (targeting $10-25MM investments in late-stage companies with completed development and regulatory programs) and the Innovation Fund (targeting $5-10MM investments in earlier-stage development phase companies). The firm actively manages a portfolio of MedTech companies across diagnostics, therapeutic devices, imaging, and healthcare IT sectors, providing capital, guidance, and board representation to portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

• BioVentures MedTech Growth Capital Fund: A fund seeking to deploy $10-25MM into companies that have removed essentially all development and regulatory risk and are entering a growth phase leading to successful exit within 3 years.
• BioVentures MedTech Innovation Fund

Products and services

• BioVentures MedTech Growth Capital Fund A growth-stage investment fund deploying $10-25MM into MedTech companies that have completed or substantially completed development and regulatory programs, are at the cusp of meaningful commercial concept or commercial growth, and target successful exit within 36 months. Targets differentiated MedTech innovation creating meaningful clinical contributions, cost-effective solutions, and rewarding exit returns, with opportunities for syndication and limited partner co-investment depending on rational use of proceeds and capital needs.
• BioVentures MedTech Innovation Fund An early-stage MedTech investment fund deploying $5-10MM, often across multiple tranches/rounds, into companies in the development phase with anticipated exits within 4-6 years. Targets companies with novel applications and breakthrough technologies aimed at improving patient health, easing physician implementation, and reducing healthcare delivery costs, with opportunities for syndication and limited partner co-investment.

Quantifiable outcome

• 30+ investment opportunities in MedTech sector with 20+ successful exits

Named customers10 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Santé Ventures: Sante Ventures is a healthcare-focused venture capital firm investing in early- and growth-stage medical device and digital health companies. Directly comparable to BioVentures given similar MedTech concentration, check sizes, and focus on commercial-stage de-risking.
• Accuitive Medical Ventures: Accuitive Medical Ventures is a venture capital firm exclusively dedicated to investing in medical device and MedTech companies. Closely comparable to BioVentures in sector focus, target stage, and investment thesis around commercial execution.
• Aperture Venture Partners: Aperture Venture Partners is a MedTech-focused early- and growth-stage investor targeting emerging medical device, diagnostic, and digital health companies. Highly comparable investment scope and stage to BioVentures' Innovation and Growth Capital Funds.
• Longitude Capital: Longitude Capital is a healthcare-focused growth equity firm investing in commercial-stage medical device, diagnostics, and specialty pharma companies. Comparable growth-stage MedTech mandate and check size to BioVentures' Growth Capital Fund.
• Emergent Medical Partners: Emergent Medical Partners is a MedTech-focused venture capital firm investing in early- and growth-stage medical device companies. Closely comparable to BioVentures in sector specialization and stage orientation.

Broad incumbents

• Versant Ventures: Versant Ventures is a healthcare-dedicated venture firm with multiple funds across biotech, MedTech, and healthcare services. Larger and broader than BioVentures but overlaps materially in MedTech growth-stage investing.
• OrbiMed: OrbiMed is a leading healthcare investment platform with multi-billion AUM across venture, growth, and public strategies. Comparable in MedTech/medical device focus but operates at materially larger scale than BioVentures.
• SV Health Investors: SV Health Investors is a healthcare-focused venture and growth firm with deep medical device and biotech expertise. Broader portfolio and larger AUM than BioVentures but overlapping MedTech investment thesis.
• HealthCare Royalty Partners: HealthCare Royalty Partners is a healthcare-focused investment firm with strategies across royalties, growth equity, and venture. Overlaps with BioVentures in healthcare growth-stage investing but operates with broader financial structures.

Regional players

• Ascension Ventures: Ascension Ventures is the strategic venture arm of Ascension Health, investing in healthcare technology and MedTech companies. Comparable sector focus but distinguished by its health system LP base and strategic sourcing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioventures Investors